IMU

0.00%

5.5¢ imugene limited

The CF33, Vaxinia and Oncarlytics Deal, page-1031

First 1031 Last

Share
Profile

Follow
kira1256

160 Posts.

42

02/11/23

21:05

Post #: 70699433
Share

Originally posted by Mason14: ↑

Lot's of talking going on here.

I'm wondering if anyone has addressed the fact that there is limited preclinical evidence that has demonstrated a significant benefit from intravenous administration of CF33 either as a single agent or in combination with an anti-PDL1 in every murine model tested? In cases were there may have been benefit, the clinical trial either administered the OV/combination immediately after transfection into the murine model or did not have a single-agent PDL1 arm.

Intratumoral administration of anti-cancer agents for metastatic cancers is not and has never been an effective method of administration. In metastases, cancer has spread around the body and in most cases the cancer sites are not accessible by a needle (just look below). Notice in the most recent announcement that they only accepted patients that had cancers close to the skin, and it was those specific cancer locations they were examining. Need I say that cancers in early stages that are close to the skin are removed surgically, so who exactly is your target market?

Oncolytic viral therapy has always struggled to penetrate the tumor microenvironment, survive the immune system, and display significant efficacy in the clinic, which is why it's worth just $23-84M globally. Not to mention it is a crowded space with 114 clinical trials currently underway.

If CF33 as a single agent or in combination with any drug can't demonstrate a significant benefit administered intravenously, then it will fail in the clinic and commercialisation. I think IMU is about to head below 10c as people begin to understand the significant clinical and commercial risks associated with CF33, and with the realisation that HER-VAXX was a substandard therapy hyped as superior.

Expand

Wow, this person has been consistently accurate with their predictions.

IMU Price at posting: 4.3¢ Sentiment: Sell Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Time for retail therapy in the shopping Scentre for some hot stocks

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

There are more pages in this discussion • 57 more messages in this thread...

First 1031 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.5¢		Change 0.000(0.00%)		Mkt cap ! $402.5M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	5431	6.0¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	40430	2

View Market Depth

No.	Vol.	Price($)
2	5431	0.060
4	170060	0.057
4	320126	0.056
16	1017985	0.055
21	1700535	0.054

Price($)	Vol.	No.
0.050	40430	2
0.054	5000	1
0.055	111000	1
0.056	126955	3
0.057	1245576	7

Last trade - 10.04am 25/06/2024 (20 minute delay)

IMU (ASX) Chart

Day chart unavailable

The CF33, Vaxinia and Oncarlytics Deal, page-1031

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Time for retail therapy in the shopping Scentre for some hot stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The CF33, Vaxinia and Oncarlytics Deal, page-1031

Top Stories

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Time for retail therapy in the shopping Scentre for some hot stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News